PRODUCT

THERAPEUTICS

ABOUT US

Treating Opioid Use Disorder Remains Challenging

The most evidence-based approach to treating Opioid Use Disorder (OUD) involves prescription Buprenorphine. Unfortunately the patient population is often non-compliant with their Rx. The challenges of managing these patients negatively impact both outcomes and access.

Insufficient Adherence to Treatment Evidence indicates:

Prevalent underuse and overuse
Daily compliance estimates of 72% or less

Widespread diversion of buprenorphine, accounting for nearly 50% of buprenorphine prescribed.

Frequently contributing to high rates of relapse

A Better Treatment Option

Our smart drug-device product is comprised of pre-packaged buprenorphine/naloxone secure cartridges and a SmartKey programmed by the dispensing pharmacy.

Easy prescribing and pharmacy dispensing

Certified pharmacy partners handle system set-up and distribution

Guiding compliance and enforcing flow control

Providers can prescribe a target dose and maximum limit, while the SmartKey guides the patient

Usage Tracking and Reporting

Clinicians have continuous access to reports on medication usage patterns

Improve drug safety, risk stratification, and patient engagement

Treatment Adherence Program

Encouraging proper access via monitoring and dose by dose access control

Risk-Assessment Reports

Reveal patterns of poor compliance, misuse, or tampering; Satisfy FDA REMS requirements and DEA recordkeeping rules

Unauthorized Access Deterrence

Oral buprenorphine products have elevated rates of child poisoning. Secure cartridges deter unauthorized access by children and others

Higher Compliance Rate

MedicaSafe patients took medication as prescribed 97% of days (CI 94% to 100%), versus reference TAU rate of 72% (CI 68% to 76%).

97%

Medication Compliance

6.8 / 7

Satisfaction Rating

MedicaSafe Can Help

Better Compliance

“Accountability is a variable that increases the likelihood that a person is going to do the right thing. Sometimes their mindset isn’t quite there yet, but working with MedicaSafe system over period of time brings more people into compliance with the system.”

Dr. Ross Fishman,
PhD, Director of Innovative Health Services

Patient Perspective

“My biggest concern was coming off opioids and doing it the right way without causing any harm to my body and obviously doing it in a safe way. I’m married, have a kid, and I didn’t want any kind of negative influence or drugs in the house that could potentially get in his hands.”

Ajay, Patient

We Help Patients Stay on Track

Our system motivates the patient to comply with their medication regimen, which in turn can lead to positive long-term outcomes

Unprecedented Insight

Dose-by-dose dispensing data, when used in conjunction with lab tests, can enable unambiguous detection of misuse and diversion

Opioid Misuse Epidemic

Annual opioid misuse

12m

OUD Patients in treatments

1.1m

Compliance rate is only

72%

Annual opioid overdose increase rate

30%

More than 115 Americans die every day from an opioid overdose. The misuse of and addiction to opioids including prescription pain relievers, heroin, and synthetic opiois such as fentanyl is a serious national crisis that affects public health as well as social and economic welfare.

The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse along in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

There's effective treatment for opioid addiction

Buprenorphine is the only opioid substitute approved for office-based treatment of opioid use disorder (OUD)

Addressing Prescriber Concerns

Surveyed buprenorphine prescribers (N>30) indicate they would use MedicaSafe with roughly 50% of their patients

We are building something great and are looking for great minds

PRODUCT

THERAPEUTICS

ABOUT US

Treating Opioid Use Disorder Remains Challenging

The most evidence-based approach to treating Opioid Use Disorder (OUD) involves prescription Buprenorphine. Unfortunately the patient population is often non-compliant with their Rx. The challenges of managing these patients negatively impact both outcomes and access.

Insufficient Adherence to Treatment Evidence indicates:

Prevalent underuse and overuse
Daily compliance estimates of 72% or less

Widespread diversion of buprenorphine, accounting for nearly 50% of buprenorphine prescribed.

Frequently contributing to high rates of relapse

A Better
Treatment Option

Our smart drug-device product is comprised of pre-packaged buprenorphine/naloxone secure cartridges and a SmartKey programmed by the dispensing pharmacy.

Easy prescribing and pharmacy dispensing

Certified pharmacy partners handle system set-up and distribution

Guiding compliance and enforcing flow control

Providers can prescribe a target dose and maximum limit, while the SmartKey guides the patient

Usage Tracking and Reporting

Clinicians have continuous access to reports on medication usage patterns

Improve drug safety, risk stratification, and patient engagement

Treatment Adherence Program

Encouraging proper access via monitoring and dose by dose access control

Risk-Assessment Reports

Reveal patterns of poor compliance, misuse, or tampering; Satisfy FDA REMS requirements and DEA recordkeeping rules

Unauthorized Access Deterrence

Oral buprenorphine products have elevated rates of child poisoning. Secure cartridges deter unauthorized access by children and others

Higher
Compliance Rate

MedicaSafe patients took medication as prescribed 97% of days (CI 94% to 100%), versus reference TAU rate of 72% (CI 68% to 76%).

97%

Medication Compliance

6.8 / 7

Satisfaction Rating

MedicaSafe Can Help

Better Compliance

“Accountability is a variable that increases the likelihood that a person is going to do the right thing. Sometimes their mindset isn’t quite there yet, but working with MedicaSafe system over period of time brings more people into compliance with the system.”

Dr. Ross Fishman,
PhD, Director of Innovative Health Services

Patient Perspective

“My biggest concern was coming off opioids and doing it the right way without causing any harm to my body and obviously doing it in a safe way. I’m married, have a kid, and I didn’t want any kind of negative influence or drugs in the house that could potentially get in his hands.”

Ajay, Patient

Helping Patients Stay On Track

We adapt the “Hawthorne Effect”: When clinicians can track a patient’s behavior, it can lead to better compliance.

Unprecedented Insight

Dose-by-dose dispensing data, when used in conjunction with lab tests, can enable unambiguous detection of misuse and diversion

Opioid Misuse Epidemic

12m

Annual opioid misuse

1.1m

OUD Patients in treatments

72%

Compliance Rate

30%

Annual opioid overdone increase rate

More than 115 Americans die every day from an opioid overdose. The misuse of and addiction to opioids including prescription pain relievers, heroin, and synthetic opiois such as fentanyl is a serious national crisis that affects public health as well as social and economic welfare.

The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse along in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

There's effective treatment for opioid addiction

Buprenorphine is the only opioid substitute
approved for office-based treatment of
opioid use disorder (OUD)

Addressing Prescriber
Concerns

Surveyed buprenorphine prescribers (N>30) indicate they would use MedicaSafe with roughly 50% of their patients

We are building something great and are looking for great minds

COPYRIGHT 2019 MEDICASAFE
ALL RIGHTS RESERVED